"Antihypertensive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
| Descriptor ID |
D000959
|
| MeSH Number(s) |
D27.505.954.411.162
|
| Concept/Terms |
Antihypertensive Agents- Antihypertensive Agents
- Agents, Antihypertensive
- Antihypertensives
- Anti-Hypertensives
- Anti Hypertensives
- Antihypertensive Drugs
- Drugs, Antihypertensive
- Anti-Hypertensive Agents
- Agents, Anti-Hypertensive
- Anti Hypertensive Agents
- Anti-Hypertensive Drugs
- Anti Hypertensive Drugs
- Drugs, Anti-Hypertensive
|
Below are MeSH descriptors whose meaning is more general than "Antihypertensive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antihypertensive Agents".
This graph shows the total number of publications written about "Antihypertensive Agents" by people in this website by year, and whether "Antihypertensive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2023 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antihypertensive Agents" by people in Profiles.
-
Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
-
Ten-Year Review of Antihypertensive Prescribing Practices After Stroke and the Associated Disparities From the Florida Stroke Registry. J Am Heart Assoc. 2023 Nov 21; 12(22):e030272.
-
Novel Targets for Hypertension Drug Discovery. Curr Hypertens Rep. 2021 Mar 30; 23(4):19.
-
Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications. Patient Educ Couns. 2021 07; 104(7):1756-1764.
-
Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
-
A Review of Hypertension Management in Black Male Patients. Mayo Clin Proc. 2020 09; 95(9):1955-1963.
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
-
A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2016 Jan; 22(1):63-73.
-
Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int. 2013 Nov; 84(5):931-9.